Welcome to our dedicated page for Sage Therapeutic SEC filings (Ticker: SAGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to historical U.S. Securities and Exchange Commission (SEC) filings for Sage Therapeutics, Inc. (former Nasdaq: SAGE), a biopharmaceutical company focused on brain health and postpartum depression. These documents include current reports on Form 8-K, delisting notices, and deregistration filings that together describe key corporate, regulatory, and capital markets events in the company’s history.
For Sage, recent Form 8-K filings detail the Agreement and Plan of Merger with Supernus Pharmaceuticals, Inc., the tender offer process, and the subsequent merger in which Saphire, Inc., a wholly owned subsidiary of Supernus, merged with and into Sage Therapeutics. The 8-K filed on July 31, 2025, explains that, as a result of this transaction, Sage became a wholly owned subsidiary of Supernus and that a change in control occurred. It also describes the treatment of equity awards, changes in directors and officers, and amendments to the company’s certificate of incorporation.
Filings related to Sage’s trading status are particularly important for investors researching the SAGE symbol. A Form 25 filed by The Nasdaq Stock Market LLC on July 31, 2025, covers the removal of Sage’s common stock from listing and registration on The Nasdaq Global Market under Section 12(b) of the Exchange Act. Subsequently, Sage filed a Form 15 on August 11, 2025, certifying the termination of registration of its common stock under Section 12(g) and the suspension of its reporting obligations under Sections 13 and 15(d). Together, these filings document Sage’s transition from a publicly traded company to a wholly owned subsidiary with suspended Exchange Act reporting.
Earlier and related filings, including 8-Ks furnishing quarterly financial results, provide additional context on Sage’s collaboration revenue from ZURZUVAE, research and development expenses, restructuring activities, and strategic alternatives review. On Stock Titan, AI-powered tools can help users quickly interpret these complex filings by highlighting key sections, summarizing major events such as acquisitions and delistings, and pointing to items that may be relevant for understanding Sage’s historical financial condition, changes in control, and the regulatory record associated with the SAGE ticker.
The Reporting Persons — Madison Avenue International LP, Madison Avenue Partners LP, EMAI Management, LLC, Madison Avenue GP, LLC, Caraway Jackson Investments LLC and Eli Samaha — disclosed beneficial ownership of 6,077,065 shares of Sage Therapeutics common stock, representing approximately 9.7% of the 62,620,694 shares used as the basis for the calculation. The ownership is reported as shared voting and shared dispositive power, with no sole voting or dispositive power claimed.
The statement was filed on Schedule 13G, indicating a passive stake, and includes a certification that the securities were not acquired to change or influence control of the issuer.